Windtree Therapeutics to Host Key Opinion Leader Meeting on Respiratory Distress Syndrome

WARRINGTON, Pa., June 7, 2016 /PRNewswire/ -- Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that it will host a Key Opinion Leader meeting on Tuesday, June 14, 2016 from 12:00 pm – 1:30 pm Eastern in New York City.

The meeting will feature Neil N. Finer, MD, a widely recognized expert and key opinion leader in the field of neonatal research. Dr. Finer will discuss current treatment options for respiratory distress syndrome (RDS) in premature infants. Senior members of the Windtree Therapeutics executive management team will provide an overview of the Company's AEROSURF® phase 2 clinical development program for the treatment of premature infants with RDS and the potential market opportunity for AEROSURF.

Dr. Finer is currently Professor Emeritus, University of California, San Diego (UCSD) School of Medicine. From 1995 to 2013 he was a Professor and Director, Neonatology for the UCSD School of Medicine, and he subsequently became a senior research associate at the Neonatal Research Institute at Sharp Mary Birch Hospital for Women and Newborns, the largest delivery hospital in California, where he continues to develop and implement new research programs. He did his Pediatric Residency and Pulmonary/Neonatal Fellowship at Children's Hospital Medical Center, Harvard Medical School.  Dr. Finer was a member of the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network (NRN), a collaborative network of neonatal intensive care units across the United States focused on facilitating the advancement of neonatal care.  While at the NRN, he became the Principal Investigator for the SUPPORT trial, the largest randomized trial to compare early nasal continuous positive airway pressure (nCPAP) with early surfactant in premature infants. He is also the current Chair of the AEROSURF® Steering Committee.

Dr. Finer has spent most of his career caring for very premature and/or unstable newborn infants. He has helped define the most significant clinical problems requiring new and better approaches in caring for these infants and has performed extensive research in the use of nCPAP and surfactant therapy for RDS. He has authored more than 260 peer-reviewed publications.

The event is intended for institutional investors and sell-side analysts only. If you would like to attend in person, please contact Mac MacDonald at 212-915-2567 or via e-mail at [email protected] to reserve a place.

A live webcast of the event, with slides, will be available at http://lifesci.rampard.com/20160614_windtree and in the Investors section of the Company's website at http://windtreetx.investorroom.com/events. A replay of the webcast will be available on the Company's website.

About AEROSURF®
Windtree's lead product candidate is AEROSURF, a novel, investigational drug/device product that combines the Company's proprietary KL4 surfactant and aerosolization technologies.  AEROSURF is being developed to potentially reduce or eliminate the need for endotracheal intubation and mechanical ventilation in the treatment of premature infants with respiratory distress syndrome (RDS).  Enrollment is ongoing in a  phase 2b clinical trial in up to 240 premature infants to study AEROSURF in premature infants 26 to 32-week gestational age receiving nasal continuous positive airway pressure (nCPAP) for RDS, compared to infants receiving nCPAP alone.  The phase 2b trial is a global trial with clinical sites in North America, Europe and Latin America.

About Windtree Therapeutics
Windtree Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel surfactant therapies for respiratory diseases and other potential applications. Windtree's proprietary technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant and novel drug-delivery technologies being developed to enable noninvasive administration of aerosolized KL4 surfactant. Windtree is focused initially on improving the management of respiratory distress syndrome (RDS) in premature infants and believes that its proprietary technology may make it possible, over time, to develop a pipeline of KL4 surfactant product candidates to address a variety of respiratory diseases for which there are few or no approved therapies.

For more information, please visit the Company's website at www.windtreetx.com.

SOURCE Windtree Therapeutics, Inc.

Related Links

http://www.discoverylabs.com